UCLA develops scalable TCR therapy for solid tumors using cord blood stem cells

A team at UCLA has engineered a new approach to fighting solid tumors—cancers that have largely resisted the wave of immunotherapies that have transformed treatment for blood cancers. The work, published in Cell Reports Medicine, centers on a type of immune cell therapy called TCR therapy, which works by genetically reprogramming T cells to recognize and destroy cancer cells with precision.

The distinction between TCR therapy and its better-known cousin, CAR T-cell therapy, matters for solid tumors specifically. CAR T-cell therapy can only spot proteins that sit on the outside of cancer cells, like flags on a flagpole. TCR therapy, by contrast, can detect protein fragments that originate deep inside the cancer cell and get transported to the surface, where they appear like name tags. For solid tumors, where most of the cellular machinery that drives cancer is hidden internally, this difference opens access to far more potential targets. But the existing versions of TCR therapy carry a steep practical cost: each dose must be custom-manufactured from a patient's own T cells, a process taking weeks and running into six figures per patient. Researchers have explored using donor-derived T cells instead, which could theoretically be made in advance and used off-the-shelf for many patients. That approach, however, carries a serious risk—graft-versus-host disease, a condition in which the transplanted immune cells attack the patient's own healthy tissues.

The UCLA team found a way around both problems at once. Rather than starting with mature T cells—either from the patient or from a donor—they began one step earlier, with blood stem cells harvested from donated umbilical cord blood. These stem cells are undifferentiated; they haven't yet become specialized immune cells with fixed receptors already in place. The researchers engineered these stem cells to carry a gene for a receptor that targets NY-ESO-1, a protein present in many solid tumors. They then grew these modified stem cells into T cells in the laboratory. The key advantage of this approach is timing: by introducing the cancer-targeting receptor early, before the stem cells differentiate into mature T cells, the researchers ensure that essentially all of the resulting cells carry the same receptor and pursue the same tumor target. This contrasts sharply with conventional donor-derived T-cell therapies, which start from T cells that already carry a random collection of natural receptors—receptors that must then be silenced through additional gene editing to prevent them from attacking healthy tissue.

The engineered cells, called AlloESO-T cells, carry a second layer of defense as well. Beyond the NY-ESO-1 targeting system, they also possess natural killer cell receptors—a separate detection mechanism that recognizes stress signals many tumor cells display on their surface. This backup system matters because solid tumors are notorious for shedding or hiding the very markers a therapy is designed to find, a phenomenon researchers call antigen escape. When a tumor cell loses or conceals the NY-ESO-1 name tag, the natural killer receptors provide an independent route to recognition and destruction. In laboratory tests against human melanoma, ovarian, and prostate cancer cells, this dual mechanism allowed the engineered cells to destroy tumor cells that the primary NY-ESO-1 pathway alone could not catch.

In mouse models, the results were striking. In ovarian cancer models, a single dose of AlloESO-T cells produced durable tumor control and extended survival. A comparison group treated with T cells engineered from mature donor T cells achieved only partial tumor control and developed graft-versus-host disease. The melanoma model told the same story: the AlloESO-T cells slowed cancer growth and delayed recurrence, while the conventionally engineered cells offered only temporary control. The difference in behavior was revealing. After a single infusion, the AlloESO-T cells multiplied roughly 100-fold, traveled to the tumor site, expanded where they were needed, and remained active for weeks while largely sparing healthy organs. The conventionally engineered cells, by contrast, spread through the liver and lungs and triggered the toxicity the new approach was designed to avoid.

Perhaps the most transformative aspect of this platform is its scalability and cost. Because the therapy begins with stem cells rather than fully formed T cells collected one patient at a time, manufacturing can operate at a scale that custom-made therapies cannot match. From a small number of cord blood stem cells, the researchers can generate trillions of therapeutic cells—enough for thousands of doses—within approximately six weeks. At an estimated five thousand dollars per dose, this approach would be far more accessible than current therapies, which often cost well into the six figures. The researchers frame this not as a single therapy for a single target, but as a platform. As long as a receptor for a given cancer antigen has been validated, it can be built into this system to generate T cells specific to that target. For patients with solid tumors that lack good targets naturally appearing on their surface—cancers that have historically offered few options—this platform could open new treatment pathways.